Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) Income towards Parent Company (2023 - 2024)

Sagimet Biosciences has reported Income towards Parent Company over the past 2 years, most recently at -$16.2 million for Q4 2024.

  • Quarterly results put Income towards Parent Company at -$16.2 million for Q4 2024, down 98.74% from a year ago — trailing twelve months through Dec 2024 was -$45.6 million (down 63.45% YoY), and the annual figure for FY2025 was -$51.0 million, down 12.01%.
  • Income towards Parent Company for Q4 2024 was -$16.2 million at Sagimet Biosciences, down from -$14.6 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for SGMT hit a ceiling of -$6.4 million in Q3 2023 and a floor of -$16.2 million in Q4 2024.